Agios Pharmaceuticals recently released its 10-Q report. The Cambridge, Massachusetts-based biopharmaceutical company focuses on cellular metabolism and rare blood disorders, with commercial products PYRUKYND (mitapivat) and AQVESME and a pipeline that includes tebapivat, AG-181 and AG-236. Its lead drug, mitapivat, is approved in the U.S. for hemolytic anemia in adults with pyruvate kinase deficiency and for alpha* or beta-thalassemia, while the company is also pursuing additional indications in sickle cell disease and pediatric PK deficiency.
For the three months ended March 31, 2026, Agios reported a net loss of $99.1 million, wider than the $89.3 million loss in the same period a year earlier. The company said it continues to expect significant losses as it expands commercialization of PYRUKYND and AQVESME and advances clinical and regulatory work on mitapivat, tebapivat, AG-181 and AG-236. As of March 31, 2026, Agios had an accumulated deficit of $660.8 million.
Agios said its revenue base now comes from sales of PYRUKYND and AQVESME in the U.S., where it sells through a limited number of specialty distributors and specialty pharmacies. The company also has commercial agreements for PYRUKYND in the Gulf Cooperation Council countries through NewBridge Pharmaceuticals and in the European Economic Area, Switzerland and the U.K. through Avanzanite Bioscience. It said future revenue may also come from milestone payments, upfront payments or royalties under future collaboration or licensing deals.
In the quarter, Agios continued to frame research and development as a major cost driver, noting that later-stage programs generally require larger and longer trials. The company said it cannot reasonably estimate the timing or cost of completing development for its product candidates, citing uncertainty around clinical enrollment, regulatory approvals, manufacturing, patent protection and commercial launch. As a result of these announcements, the company's shares have moved -1.63% on the market, and are now trading at a price of $25.32. For the full picture, make sure to review 's 10-Q report.
